Comorbidities in MDD

CME

Comorbidity Considerations in Major Depressive Disorder and Treatment Augmentation

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 13, 2020

Expiration: April 12, 2021

Christoph U. Correll
Christoph U. Correll, MD

Activity

Progress
1
Course Completed

References

  1. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54:216-226.
  2. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31:761-777.
  3. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5™. 5th edition. Washington, DC: American Psychiatric Publishing, Inc; 2013.
  4. Centers for Disease Control and Prevention and National Association of Chronic Disease Directors. The state of mental health and aging in America. Issue Brief 2: addressing depression in older adults: selected evidence-based programs. Available at: https://www.cdc.gov/aging/pdf/mental_health_brief_2.pdf. Accessed March 29, 2020.
  5. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs. 2009;23:583-602.
  6. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-137.
  7. Lupinno FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220-229.
  8. Meng L, Chen D, Yang Y, et al. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens. 2012;30:842-851.
  9. Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383-2390.
  10. Cuijpers P, Vogelzangs N, Twisk J, et al. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry. 2014;171:453-462.
  11. Correll CU, Solmi M, Veronese N. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163-180.
  12. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
  13. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-186.
  14. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139;230-239.
  15. Volgelzangs N, Duivis HE, Beekman AT, et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2012;2:e79.
  16. Chauvet-Gélinier JC, Trojak B, Vergès-Patois B, et al. Review on depression and coronary heart disease. Arch Cardiovasc Dis. 2013;106:103-110.
  17. Spieker LE, Hürlimann D, Ruschitzka F, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation. 2002;105:2817-2820.
  18. Laghrisse-Thode F, Wagner WR, Pollock BG, et al. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry. 1997;42:290-295.
  19. Sanner JE, Frazier L. The role of serotonin in depression and clotting in the coronary artery disease population. J Cardiovasc Nurs. 2011;26:423-429.
  20. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol. 2011;36:2452-2459.
  21. Hiles SA, Baker AL, de Malmanche T, et al. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med. 2012;42:2015-2026.
  22. Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl). 2016;233:1575-1589.
  23. Aripiprazole package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
  24. Brexpiprazole package insert. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2015.
  25. Quetiapine XR package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2009.
  26. Olanzapine/fluoxetine package insert. Indianapolis, IN: Eli Lilly USA, LLC; 2019.
  27. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171-181.
  28. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64-77.
  29. Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;Epub ahead of print.
  30. Jantaratnotai N, Mosikanon K, Lee Y, et al. The interface of depression and obesity. Obes Res Clin Pract. 2017;11:1-10.
  31. LaGrotte C, Fernandez-Mendoza J, Calhoun SL, et al. The relative association of obstructive sleep apnea, obesity and excessive daytime sleepiness with incident depression: a longitudinal, population-based study. Int J Obes (London). 2016;40;1397-1404.
  32. Ashton AK, Jamerson BD, L Weinstein W, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66:96-106.
  33. McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry. 2009;70(suppl 3):5-11.
  34. Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.
  35. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
  36. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
  37. MacFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713-718.
  38. Correll CU. What are we looking for in new antipsychotics? J Clin Psychiatry. 2011;72(suppl 1):9-13.
  39. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. 2006;163:1905-1917.
  40. Koyanagi A, Carvalho AF, Gaughran F, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18:53-66.
  41. Demler TL. Treating comorbid depression in CVD patients. US Pharm. 2018;43:HS2-HS6.
  42. Davis L, Uezato A, Newell JM, et al. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21:14-18.
  43. Hunt GE, Malhi GS, Lai HMX, et al. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: systematic review and meta-analysis. J Affect Disord. 2020;266:288-304.
  44. Currie SR, Patten SB, Williams JV. Comorbidity of major depression with substance use disorders. Can J Psychiatry. 2005;50:660-666.
  45. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-49, HHS Publication No. (SMA) 13-4887. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUHmhfr2013/NSDUHmhfr2013.pdf. Accessed on March 29, 2020.
  46. Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149-2164.
  47. Tirado-Muñoz J, Farré A, Mestre-Pintó J, et al. Dual diagnosis in depression: treatment recommendations. Adicciones. 2018;30:66-76.
  48. Kim J. Psychiatric comorbidity in major depressive disorder. In: McIntyre R, editor. Major depressive disorder. Amsterdam, The Netherlands: Elsevier, Inc; 2019.
  49. Farre M. In: Preedy V, editor. The neuroscience of cocaine. Academic Press, 2017; Chapter 64.
  50. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011;30:1434-1442.